| Novartis Pharma Schweiz AG - Mayzent 0.25 mg, Filmtabletten | | 67230 | | 01 | | Mayzent 0.25 mg | | Filmtabletten | | L04AA42 | | Siponimod | | 22.10.2020 | | |
| | Composition | | siponimodum 0.25 mg ut siponimodi fumaras, lactosum monohydricum 62.197 mg, cellulosum microcristallinum, crospovidonum, glyceroli dibehenas, silica colloidalis anhydrica, Überzug: poly(alcohol vinylicus), talcum, lecithinum ex soja, xanthani gummi, E 171, E 172 (rubrum), E 172 (nigrum), pro compresso obducto. | | Packungsbestandteile | | Comprimés filmés | | | | | Principe actif | Concentr. |
|---|
| Siponimodum | 0.25 mg |
| | BAG: Principe actif | Concentr. |
|---|
| Siponimodum | 0.25 mg |
| | | | Agents auxilliaires | Concentr. | informations additionels |
|---|
| (Nigrum) | | | | (Rubrum) | | | | Cellulosum Microcristallinum | | | | Crospovidonum | | | | E 171 | | color. | | E 172 | | color. | | Glyceroli Dibehenas | | | | Lactose Monohydrate | 62.197 mg | | | Lecithinum ex Soja | | | | Poly(Alcohol Vinylicus) | | Überzug | | Pro Compresso Obducto | | | | Silica Colloidalis Anhydrica | | | | Talcum | | | | Xanthani Gummi | | |
| |
| |
|
